Michael Kallen

Dr. Michael Kallen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
MKMichael Kallen
Michael Kallen
MMMichael Michal
Michael Michal
AMAnders Meyer
Anders Meyer
DSDavid I. Suster
David I. Suster
NONicholas J. Olson
Nicholas J. Olson
JGJohn M. Gross
John M. Gross
Calcified chondroid mesenchymal neoplasm is a term proposed for tumors with a spectrum of morphologic features, including cartilage/chondroid matrix formation, that frequently harbor FN1 gene fusions. We report a series of 33 cases of putative calcified chondroid mesenchymal neoplasms, mostly referred for expert consultation out of concern for malignancy. Patients included 17 males and 16 females, with a mean age of 51.3 years. Anatomic locations include the hands and fingers, feet and toes, head and neck, and temporomandibular joint; 1 patient presented with multifocal disease. Radiologic review showed soft tissue masses with variable internal calcification, which occasionally scalloped bone but in all cases appeared indolent/benign. Tumors had a mean gross size of 2.1 cm and a homogenous rubbery to fibrous/gritty tan-white cut surface. Histology demonstrated multinodular architecture with a prominent chondroid matrix and increased cellularity towards the periphery of the nodules. The tumor cells were polygonal with eccentric nuclei and bland cytologic features and showed a variable amount of increased spindled / fibroblastic forms in the perinodular septa. The majority of cases had notable grungy and/or lacy calcifications. A subset of cases demonstrated at least focal areas of increased cellularity and osteoclast-like giant cells. Herein, we confirm the distinct morphologic and clinicopathologic features associated with this entity with the largest series to date, with a focus on practical diagnostic separation from similar chondroid neoplasms. Awareness of these features is critical in avoiding pitfalls, including a malignant diagnosis of chondrosarcoma.

9 April 2022 in Journal of Pediatric Psychology
Verified
Journal Article
Open access
PDF file
JLJin-Shei Lai
Jin-Shei Lai
MKMichael Kallen
Michael Kallen
CBCourtney Blackwell
Courtney Blackwell
LWLauren S Wakschlag
Lauren S Wakschlag
DCDavid Cella
David Cella
The early expression of lifespan health and disease states can often be detected in early childhood. Currently, the Patient-Reported Outcome Measurement Information System (PROMIS®) includes over 300 measures of health for individuals ages 5 years and older. We extended PROMIS to early childhood by creating developmentally appropriate, lifespan coherent parent-report measures for 1–5-year-olds. This paper describes the psychometric approaches used for these efforts; 2 waves of data from parents of children ages 1–5 were collected via 2 internet panel companies. Wave 1 data (n = 1,400) were used to evaluate item pool unidimensionality, model fit, and initial item parameters. Combined data from wave 1 and wave 2 (reference sample; n = 1,057) were used to estimate final item parameters. Using item response theory methods, we developed and tested 12 item pools: Global Health, Physical Activity, Sleep Disturbance, Sleep-related Impairment, Anger/Irritability, Anxiety, Depressive Symptoms, Positive Affect, Self-Regulation, Engagement, Family Relationships, and Peer Relationships; Wave 1 analyses supported the unidimensionality of Physical Activity, Positive Affect, Anger/Irritability, Anxiety, Depressive Symptoms, and Global Health. Family Relationships and Peer Relationships were combined to form “Social Relationships”; Sleep Disturbance and Sleep-related Impairment were combined to form “Sleep Problems.” Self-Regulation was divided into “Flexibility” and “Frustration Tolerance”; Engagement was divided into “Curiosity” and “Persistence.” Short forms were developed for item banks with more than 10 items; and Using rigorous mixed-methods, we successfully extended PROMIS to early childhood (1–5-year-olds). Measures are now publicly available in English and Spanish (www.healthmeasures.net).

16 August 2023 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
YNYi Ning
Yi Ning
YZYanming Zhang
Yanming Zhang
MKMichael Kallen
Michael Kallen
AEAshkan Emadi
Ashkan Emadi
BRBaer M R
Baer M R

1 February 2021 in Histopathology
Verified
Journal Article
Closed access
PDF file
LSLinda Song
Linda Song
KSKristen M. Stashek
Kristen M. Stashek
ABAmin Benyounes
Amin Benyounes
DDDerik L. Davis
Derik L. Davis
MMMichael E Mulligan
Michael E Mulligan
MKMichael Kallen
Michael Kallen

1 November 2022 in Leukemia Research Reports
Verified
Journal Article
Open access
MKMichael Kallen
Michael Kallen
RKRima Koka
Rima Koka
ZSZeba N. Singh
Zeba N. Singh
YNYi Ning
Yi Ning
MKMehmet H. Kocoglu
Mehmet H. Kocoglu
MBMaria R. Baer
Maria R. Baer
New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myeloma, which included lenalidomide maintenance. A subset of patients had pancytopenia and low-level marrow involvement by acute leukemia, an unusual finding in de novo B-ALL. One patient died of chemotherapy complications; the other seven responded. No patient died of B-ALL (median follow up of 1.0 years). Our series suggests that t-B-ALL is clonally unrelated to myeloma, presents with diverse cytogenetic abnormalities, and responds well to B-ALL therapy.

15 August 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
KGKathleen L. Grady
Kathleen L. Grady
MKMichael Kallen
Michael Kallen
DBDavid G. Beiser
David G. Beiser
JLJoAnn Lindenfeld
JoAnn Lindenfeld
JTJeffrey Teuteberg
Jeffrey Teuteberg
EHElizabeth A. Hahn
Elizabeth A. Hahn